Sun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for t...

Sun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis....

Sun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This nov...

Bank of America downgraded Sun Pharma stock to ‘underperform’ from ‘neutral’, citing risks to premium valuations and slower speciality exec...

JM Financial maintains a Buy call on Sun Pharmaceutical Industries, setting a revised target price of Rs 2025. Sun Pharma's Q4FY25 results ...

In a regulatory filing, Sun Pharmaceutical Industries said its "wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection...

Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA...

The drug maker had reported a loss of Rs 269.60 crore in the corresponding quarter last year.

Centrum Broking expects Sun Pharma's India sales to grow at 7 per cent for the quarter.

Reduce Sun Pharmaceutical Industries at a price target of Rs 450.

Buy Sun Pharmaceutical Industries at a price target of Rs 581.

Sun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...

Last year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.

The company informed stock exchanges about the USFDA nod after market hours of Wednesday.

Equity market opened on a positive note after US Fed hiked interest rate by 25 bps.

The drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...

The FDA approval of the drug was supported by data from the pivotal phase-3 resurface clinical development program, it said.